sublingual delivery glp-1 receptor agonists Schematic illustration of monoagonists, dual and triple GLP-1 and Anesthesia: Considerations and

Theres also a noted risk for thyroid cancer

Stiewig-Rapp is the incoming director of a new Obesity Clinic the health system is set to open in 2026

Several GLP-1 medications were first approved for type 2 diabetes, but some patients were later prescribed off-label versions of these drugs for weight loss before separate obesity-specific formulations became available

KFFs analysis of newly released Medicare Part D spending data from CMS shows that total gross Medicare spending on the three newest versions of these diabetes medications that have also been recently approved for weight loss Ozempic, Rybelsus, and Mounjaro has skyrocketed in recent years, rising from $57 million in 2018 to $5.7 billion in 2022 (Figure 1)

Oral semaglutide likewise resulted in reductions in weight during the trial